The influence of HER2 genotypes as molecular markers in ovarian cancer outcome

被引：30

作者：

Pinto, D ^{[1
]}

Pereira, D

Portela, C

da Silva, JL

Carlos, LA

Medeiros, R

机构：

[1] Portuguese Inst Oncol, Pathol & Mol Oncol Unit, Oporto, Portugal

[2] Portuguese Inst Oncol, Dept Med Oncol, Oporto, Portugal

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2005年 / 335卷 / 04期

关键词：

HER2; polymorphisms; ovarian cancer; molecular markers; pharmacogenomics;

D O I：

10.1016/j.bbrc.2005.08.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A relevant clinical problem in the treatment of ovarian cancer (OC) is the development of resistance to chemotherapy, frequently due to genetic variations in enzymes and receptors. Changes in the HER2 receptor have been associated with breast and ovarian cancers. The role of a polymorphism in the HER2 gene in the clinical outcome of OC patients was investigated in this study. We characterized DNA samples from 111 patients with OC treated with cisplatin and paclitaxel, using PCR-RFLP. Our results indicate that patients carrying the valine homozygotic genotype present a lower overall survival mean, suggesting a role for this polymorphism in the outcome of ovarian cancer patients. The G allele has been implicated in the formation of active HER2 receptors, with a more aggressive phenotype. We hypothesize that HER2 genotypes can be predictive biomarkers in ovarian cancer, contributing to a genetic individual profile of great interest in clinical oncology. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：1173 / 1178

页数：6

共 32 条

[1] Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells [J].

Abuharbeid, S ;

Apel, J ;

Sander, M ;

Fiedler, B ;

Langer, M ;

Zuzarte, ML ;

Czubayko, F ;

Aigner, A .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 321 (02) :403-412

[2] THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].

AKIYAMA, T ;

SUDO, C ;

OGAWARA, H ;

TOYOSHIMA, K ;

YAMAMOTO, T .

SCIENCE, 1986, 232 (4758) :1644-1646

[3] Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk [J].

Ameyaw, MM ;

Thornton, N ;

McLeod, HL .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (23) :1947-1947

[4]

ARTEAGA CL, 1994, CANCER RES, V54, P3758

[5] Ovarian surface epithelium: Biology, endocrinology, and pathology [J].

Auersperg, N ;

Wong, AST ;

Choi, KC ;

Kang, SK ;

Leung, PCK .

ENDOCRINE REVIEWS, 2001, 22 (02) :255-288

[6] MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].

BARGMANN, CI ;

HUNG, MC ;

WEINBERG, RA .

CELL, 1986, 45 (05) :649-657

[7] Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism [J].

Catarino, R ;

Matos, A ;

Pinto, D ;

Pereira, D ;

Craveiro, R ;

Vasconcelos, A ;

Lopes, C ;

Medeiros, R .

CANCER GENETICS AND CYTOGENETICS, 2005, 160 (01) :49-54

[8] Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3 [J].

Chen, XM ;

Yeung, TK ;

Wang, ZX .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 277 (03) :757-763

[9] TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].

COUSSENS, L ;

YANGFENG, TL ;

LIAO, YC ;

CHEN, E ;

GRAY, A ;

MCGRATH, J ;

SEEBURG, PH ;

LIBERMANN, TA ;

SCHLESSINGER, J ;

FRANCKE, U ;

LEVINSON, A ;

ULLRICH, A .

SCIENCE, 1985, 230 (4730) :1132-1139

[10] G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancer [J].

Duarte, I ;

Santos, A ;

Sousa, H ;

Catarino, R ;

Pinto, D ;

Matos, A ;

Pereira, D ;

Moutinho, J ;

Canedo, P ;

Machado, JC ;

Medeiros, R .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 334 (02) :588-592

← 1 2 3 4 →